Clough Capital Partners L P Crispr Therapeutics Ag Call Options Transaction History

Clough Capital Partners L P

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $11.3 Million - $18 Million	-161,700 Reduced 66.68%	80,800 $6.12 Million
Q2 2021 Aug 16, 2021	BUY	$100.84 - $161.89 $13.5 Million - $21.6 Million	133,500 Added 122.48%	242,500 $39.3 Million
Q1 2021 May 17, 2021	BUY	$110.72 - $210.04 $1.3 Million - $2.46 Million	11,700 Added 12.02%	109,000 $13.3 Million
Q2 2020 Aug 14, 2020	SELL	$38.5 - $76.05 $4.2 Million - $8.3 Million	-109,100 Reduced 52.86%	97,300 $7.15 Million
Q1 2020 May 15, 2020	BUY	$33.68 - $62.53 $3.79 Million - $7.03 Million	112,500 Added 119.81%	206,400 $8.75 Million
Q3 2019 Nov 14, 2019	SELL	$40.99 - $52.56 $2.55 Million - $3.26 Million	-62,100 Reduced 39.81%	93,900 $3.85 Million
Q2 2019 Aug 14, 2019	BUY	$35.45 - $48.2 $5.53 Million - $7.52 Million	156,000 New	156,000 $7.35 Million

489

57.9M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.16B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Clough Capital Partners L P, based on Form 13F filings with the SEC.

Stay updated on Clough Capital Partners L P with notifications on news.